IP Library Granted Patent US 8,541,389
Granted Patent B2
US 8,541,389 · App. 13/035,147 · Granted Sep 24, 2013

RNAi-mediated inhibition of tumor necrosis factor α-related conditions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,389
App. No.
13/035,147
Granted
Sep 24, 2013
Kind
B2
Abstract

RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.

Claims (9)

1. A method of treating a TNFα-related ocular condition in a subject in need thereof, comprising:

administering to an eye of the subject a composition beginning at an effective amount of interfering RNA having a length of 19 to 49 nucleotides, and a pharmaceutically acceptable carrier, the interfering RNA comprising a sense nucleotide strand, an antisense nucleotide strand, and the sense and antisense strands comprise a region of least near-perfect contiguous complementarity of at least 19 nucleotides;

wherein the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:2 comprising nucleotide 2048;

wherein the TNFα-related ocular condition is treated thereby, and wherein the TNFα-related ocular condition is dry eye, allergic conjunctivitis or ocular inflammation.

2. The method of claim 1 , wherein the sense nucleotide strand and the antisense nucleotide strand are connected by a loop nucleotide strand.

3. The method of claim 1 , wherein the composition is administered via an intraocular ocular, or tropical route.

4. The method of claim 1 , wherein the interfering RNA is administered via in vivo expression from an expression vector capable of expressing the interfering RNA.

5. The method of claim 1 , wherein each strand of the siRNA molecule is independently about 19 nucleotides to about 25 nucleotides in length.

6. The method of claim 1 , wherein each strand of the siRNA molecule is independently about 19 nucleotides to about 21 nucleotides in length.

Assignments (3)
CHANGE OF NAME Recorded Aug 12, 2024
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068551/0490 →
SECURITY INTEREST Recorded Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: ALCON RESEARCH, LTD.
To: ARROWHEAD RESEARCH CORPORATION
Reel/Frame 035653/0635 →